Skip to main content

Table 1 AHS consensus statement–defined clinically meaningful improvements on the HIT-6 and MIDAS [7]

From: Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies

Assessment tool

Meaningful improvement as defined by AHS Consensus Statement

HIT-6

• Reduction from baseline of ≥5 points

MIDAS

• Reduction of ≥5 points when baseline score is 11–20 (moderate disability) or

• Reduction of ≥30% when baseline score is > 20 (severe disability)

  1. AHS American Headache Society, HIT-6 6-Item Headache Impact Test, MIDAS Migraine Disability Assessment